Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul;95(28):e4151.
doi: 10.1097/MD.0000000000004151.

Adherence to Treatment of Chronic Hepatitis C: From Interferon Containing Regimens to Interferon and Ribavirin Free Regimens

Free PMC article

Adherence to Treatment of Chronic Hepatitis C: From Interferon Containing Regimens to Interferon and Ribavirin Free Regimens

Zobair M Younossi et al. Medicine (Baltimore). .
Free PMC article


Patients' experience during treatment may affect treatment adherence. Our aim was to assess the impact of patient-reported outcomes (PROs) on adherence to different anti-hepatitis C virus (HCV) regimens.Clinical, demographic, and PRO data (short form-36 [SF-36], chronic liver disease questionnaire-hepatitis C version [CLDQ-HCV], functional assessment of chronic illness therapy-fatigue [FACIT-F], work productivity and activity impairment: specific health problem [WPAI:SHP]) from 13 multinational clinical trials of anti-HCV treatment were available. Treatment adherence was defined as >80% of prescribed doses taken.Included were 4825 HCV patients. Regimens were grouped into: interferon- and ribavirin (RBV)-containing (±sofosbuvir [SOF]), interferon-free RBV-containing (RBV + SOF ± ledipasvir [LDV]), and interferon-free RBV-free (LDV/SOF). The adherence to these regimens were 77.6%, 84.3%, and 96.2%, respectively (P < 0.0001). Nonadherent patients were more likely to be unemployed and to have a greater PRO impairment at baseline (up to -5.3% lower PRO scores, P < 0.0001). During treatment with interferon- or RBV-based regimens, nonadherent patients experienced lower PROs and had larger decrements from their baseline PRO scores. In contrast, there were no significant declines in PRO scores (all P > 0.05) for the small number of patients who were nonadherent to LDV/SOF. In multivariate analysis, being treatment-naive, longer treatment duration, and receiving an interferon- or RBV-containing regimen were associated with a lower likelihood of adherence (all P < 0.003). Better baseline and on-treatment PRO scores were associated with a higher likelihood of adherence to interferon and RBV.The use of interferon and/or RBV, longer duration of treatment, and lower baseline and on-treatment PRO scores were linked to a decreased likelihood of being adherent to interferon + RBV-containing or interferon-free RBV-containing antiviral regimens. Interferon- and RBV-free regimens were associated with excellent adherence.

Conflict of interest statement

The remaining authors have no conflict of interest to disclose.


Figure 1
Figure 1
PROs in HCV patients adherent and not adherent to (A) IFN + RBV-containing regimens; (B) IFN-free RBV-containing regimens; and (C) IFN-free RBV-free regimens. CLDQ-HCV = chronic liver disease questionnaire-hepatitis C version (the total score for the instrument), FACIT-F = functional assessment of chronic illness therapy-fatigue, FS = fatigue scale of FACIT-F, HCV = hepatitis C virus, IFN = interferon, MCS = mental component summary of SF-36, PCS = physical component summary of SF-36, PRO = patient-reported outcome, RBV = ribavirin, SF-36 = short form-36.

Similar articles

See all similar articles

Cited by 15 articles

See all "Cited by" articles


    1. Patel K, McHutchison JG. Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. Cleve Clin J Med 2004; 71 suppl 3:S8–12. - PubMed
    1. Shehab TM, Fontana RJ, Oberhelman K, et al. Effectiveness of interferon alpha-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice. Clin Gastroenterol Hepatol 2004; 2:425–431. - PubMed
    1. Mravcík V, Strada L, Stolfa J, et al. Factors associated with uptake, adherence, and efficacy of hepatitis C treatment in people who inject drugs: a literature review. Patient Prefer Adherence 2013; 7:1067–1075. - PMC - PubMed
    1. LaFleur J, Hoop R, Morgan T, et al. High rates of early treatment discontinuation in hepatitis C-infected US veterans. BMC Res Notes 2014; 7:266. - PMC - PubMed
    1. Butt AA, Wagener M, Shakil AO, et al. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepat 2005; 12:81–85. - PubMed